DBV Technologies (NASDAQ:DBVT) Sets New 52-Week High Following Analyst Upgrade

DBV Technologies S.A. (NASDAQ:DBVT) hit a new 52-week high on Wednesday after Citizens Jmp raised their price target on the stock from $21.00 to $45.00. Citizens Jmp currently has a market outperform rating on the stock. DBV Technologies traded as high as $26.19 and last traded at $22.7570, with a volume of 1528755 shares. The stock had previously closed at $17.98.

DBVT has been the subject of a number of other research reports. Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Cantor Fitzgerald upgraded shares of DBV Technologies to a “strong-buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, December 8th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price objective (up previously from $20.00) on shares of DBV Technologies in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.54.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DBVT. New York State Common Retirement Fund purchased a new position in shares of DBV Technologies in the third quarter valued at about $34,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies during the third quarter valued at approximately $167,000. Citadel Advisors LLC purchased a new stake in DBV Technologies in the third quarter worth $220,000. DLD Asset Management LP bought a new stake in DBV Technologies in the third quarter valued at $250,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies during the 2nd quarter valued at $340,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Trading Up 26.4%

The company’s fifty day simple moving average is $14.98 and its 200 day simple moving average is $11.58. The firm has a market capitalization of $912.64 million, a P/E ratio of -4.40 and a beta of -1.10.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.